← back to search

Lynne D. Berry

Vanderbilt University Medical Center · US
Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, RNA modifications and cancer, Cancer Genomics and Diagnostics, and Lung Cancer Diagnosis and Treatment.
h-index
24
citations
5,805
works
82
NIH funding
primary concept
Medicine
email

Recent publications

Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps
Cell 2021cited by 332position: middledoi
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
Cell 2020cited by 584position: middledoi
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Journal of Thoracic Oncology 2019cited by 240position: middledoi
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Journal of Thoracic Oncology 2019cited by 174position: middledoi
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis
JAMA Otolaryngology–Head & Neck Surgery 2019cited by 164position: middledoi
<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Cancer 2017cited by 196position: middledoi
Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.
Journal of Clinical Oncology 2016cited by 28position: middledoi
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
Journal of Thoracic Oncology 2015cited by 427position: middledoi
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Cancer 2015cited by 114position: middledoi
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
JAMA 2014cited by 1,737position: middledoi
Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations
Clinical Cancer Research 2013cited by 142position: middledoi
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Journal of Clinical Oncology 2013cited by 60position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mark G. Kris · Kettering University8 papers (2013–2019)Paul A. Bunn · University of Colorado Denver8 papers (2013–2019)Bruce E. Johnson · Zhejiang University7 papers (2013–2019)David J. Kwiatkowski · Harvard University5 papers (2013–2019)Dara L. Aisner · University of Colorado Cancer Center4 papers (2015–2019)Edward B. Garon · Cancer Clinic4 papers (2013–2016)Suresh S. Ramalingam · Emory University4 papers (2015–2019)Lynette M. Sholl · Harvard University4 papers (2015–2019)Ignacio I. Wistuba · Disco (Germany)3 papers (2013–2016)Marc Ladanyi · Center for Cancer Research3 papers (2013–2015)John D. Minna · Weatherford College3 papers (2013–2016)Fadlo R. Khuri · Emory University3 papers (2013–2019)Wilbur A. Franklin · University of Colorado Health3 papers (2013–2015)Madhusmita Behera · Emory University3 papers (2015–2019)Michael R. Rossi · Brown University2 papers (2015–2016)Charles M. Rudin · New York Proton Center2 papers (2013–2013)A. John Iafrate · Harvard University2 papers (2013–2015)William Pao · Vanderbilt University2 papers (2013–2013)Eric B. Haura · Moffitt Cancer Center2 papers (2013–2016)Lecia V. Sequist · Harvard University2 papers (2013–2013)